Comparative Pharmacology
Head-to-head clinical analysis: UROVIST CYSTO versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROVIST CYSTO versus VISIPAQUE 320.
UROVIST CYSTO vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urovist Cysto is a radiocontrast agent containing diatrizoate meglumine and diatrizoate sodium. It provides radiographic visualization of the urinary tract by attenuating X-rays due to its iodine content. It is not systemically absorbed when used intravesically; local contrast enhancement occurs through physical properties.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Instillation of 50 mL of a 0.3% solution intravesically, retained for 10 minutes, for cystography.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Primarily renal excretion as unchanged drug (approximately 85-90% within 24 hours); minor biliary/fecal elimination (<5%).
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent